Founded to address development and delivery of new therapies and better quality of life to cancer patients, TDL Innovations, LLC bring together exceptional scientists and experienced leadership around that mission, Annually. some 200,000 people develop a devastating complication of cancer termed a Malignant Pleural Effusion ("MPE"). MPE is a build-up of fluid between the lung and the chest wall. As the fluid accumulates it compresses the lung preventing it from fully expanding, which results in severe shortness of breath and other symptoms. Typically, MPE occurs as a late-stage complication of cancer and frequently impacts the quality of life. The current therapeutic options for MPE are suboptimal as they are not always successful and can be invasive, prone to complications and burdensome to the patient. To date, Talc pleurodesis has been a common treatment strategy for MPE but is not always successful with one factor thought to reduce its effectiveness being poor dispersion of the active agent throughout the chest. TDL is developing a novel treatment to improve the delivery of talc. Pre-clinical research suggests that administration of the active agent through a foam delivery platform (Talc Foam) significantly improved pleurodesis, enhanced survival rates (compared to the Talc slurry), and reduced loss of right lung volume.
